Deborah Kay Armstrong
#161,564
Most Influential Person Now
Deborah Kay Armstrong's AcademicInfluence.com Rankings
Deborah Kay Armstrongbiology Degrees
Biology
#12831
World Rank
#16334
Historical Rank
Immunology
#863
World Rank
#886
Historical Rank
Molecular Biology
#2114
World Rank
#2146
Historical Rank
Biochemistry
#2218
World Rank
#2364
Historical Rank
Download Badge
Biology
Deborah Kay Armstrong's Degrees
- PhD Molecular Biology University of California, San Francisco
- Bachelors Biochemistry University of California, Berkeley
Why Is Deborah Kay Armstrong Influential?
(Suggest an Edit or Addition)Deborah Kay Armstrong's Published Works
Number of citations in a given year to any of this author's works
Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author
Published Works
- Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade (2017) (4313)
- Intraperitoneal cisplatin and paclitaxel in ovarian cancer. (2006) (2018)
- Survival effect of maximal cytoreductive surgery for advanced ovarian carcinoma during the platinum era: a meta-analysis. (2002) (1697)
- Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trial (2017) (1039)
- Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trial (2017) (1039)
- Taxol: a unique antineoplastic agent with significant activity in advanced ovarian epithelial neoplasms. (1989) (885)
- Prognostic factors for stage III epithelial ovarian cancer: a Gynecologic Oncology Group Study. (2007) (793)
- Phase II study of bevacizumab in patients with platinum-resistant ovarian cancer or peritoneal serous cancer. (2007) (756)
- Survival Effect of Maximal Cytoreductive Surgery for Advanced Ovarian Carcinoma During the Platinum Era: A Meta-Analysis (2002) (678)
- Recent progress in the diagnosis and treatment of ovarian cancer (2011) (676)
- Bevacizumab and paclitaxel-carboplatin chemotherapy and secondary cytoreduction in recurrent, platinum-sensitive ovarian cancer (NRG Oncology/Gynecologic Oncology Group study GOG-0213): a multicentre, open-label, randomised, phase 3 trial. (2017) (387)
- Neoadjuvant Chemotherapy for Newly Diagnosed, Advanced Ovarian Cancer: Society of Gynecologic Oncology and American Society of Clinical Oncology Clinical Practice Guideline. (2016) (371)
- Cancer yield of mammography, MR, and US in high-risk women: prospective multi-institution breast cancer screening study. (2007) (369)
- Relapsed ovarian cancer: challenges and management strategies for a chronic disease. (2002) (307)
- Intraperitoneal catheter outcomes in a phase III trial of intravenous versus intraperitoneal chemotherapy in optimal stage III ovarian and primary peritoneal cancer: a Gynecologic Oncology Group Study. (2006) (249)
- Long-term survival advantage and prognostic factors associated with intraperitoneal chemotherapy treatment in advanced ovarian cancer: a gynecologic oncology group study. (2015) (232)
- Interleukin-3 and bryostatin-1 mediate hyperphosphorylation of BCL2 alpha in association with suppression of apoptosis. (1994) (230)
- Pharmacogenomic and pharmacokinetic determinants of erlotinib toxicity. (2008) (218)
- Ovarian Cancer, Version 2.2020, NCCN Clinical Practice Guidelines in Oncology. (2021) (209)
- Ovarian cancer, version 1.2016: Clinical practice guidelines in oncology (2016) (188)
- Secondary Surgical Cytoreduction for Recurrent Ovarian Cancer. (2019) (179)
- Epidermal growth factor-mediated apoptosis of MDA-MB-468 human breast cancer cells. (1994) (179)
- Neoadjuvant chemotherapy for newly diagnosed, advanced ovarian cancer: Society of Gynecologic Oncology and American Society of Clinical Oncology Clinical Practice Guideline. (2016) (177)
- NCCN Guidelines Insights: Ovarian Cancer, Version 1.2019. (2019) (172)
- Health-related quality of life during and after intraperitoneal versus intravenous chemotherapy for optimally debulked ovarian cancer: a Gynecologic Oncology Group Study. (2007) (167)
- Phase II study of medroxyprogesterone acetate plus tamoxifen in advanced endometrial carcinoma: a Gynecologic Oncology Group study. (2004) (162)
- Germline and Somatic Tumor Testing in Epithelial Ovarian Cancer: ASCO Guideline. (2020) (155)
- Impact of surgeon and hospital ovarian cancer surgical case volume on in-hospital mortality and related short-term outcomes. (2009) (151)
- Ovarian Cancer, Version 1.2016, NCCN Clinical Practice Guidelines in Oncology. (2016) (145)
- Risk of epithelial ovarian cancer recurrence in patients with rising serum CA-125 levels within the normal range. (2005) (136)
- Prognostic factors for stage III epithelial ovarian cancer treated with intraperitoneal chemotherapy: a Gynecologic Oncology Group study. (2012) (135)
- A phase II trial of EMD72000 (matuzumab), a humanized anti-EGFR monoclonal antibody, in patients with platinum-resistant ovarian and primary peritoneal malignancies. (2007) (125)
- Farletuzumab (a monoclonal antibody against folate receptor alpha) in relapsed platinum-sensitive ovarian cancer. (2013) (124)
- Ovarian cancer, version 2.2013: Featured updates to the NCCN guidelines (2013) (122)
- Phase II trial of cetuximab and carboplatin in relapsed platinum-sensitive ovarian cancer and evaluation of epidermal growth factor receptor expression: a Gynecologic Oncology Group study. (2008) (113)
- BRCA1 expression and improved survival in ovarian cancer patients treated with intraperitoneal cisplatin and paclitaxel: a Gynecologic Oncology Group Study (2013) (112)
- A phase II evaluation of lapatinib in the treatment of persistent or recurrent epithelial ovarian or primary peritoneal carcinoma: a gynecologic oncology group study. (2012) (102)
- Secondary cytoreductive surgery for localized, recurrent epithelial ovarian cancer (2007) (99)
- Early Detection of Ovarian Cancer using the Risk of Ovarian Cancer Algorithm with Frequent CA125 Testing in Women at Increased Familial Risk – Combined Results from Two Screening Trials (2017) (95)
- A Randomized, Double-Blind, Placebo-Controlled, Phase III Study to Assess Efficacy and Safety of Weekly Farletuzumab in Combination With Carboplatin and Taxane in Patients With Ovarian Cancer in First Platinum-Sensitive Relapse. (2016) (94)
- A Primer on Continuous Renal Replacement Therapy for Critically Ill Patients (1998) (94)
- Ovarian cancer, version 3.2012. (2012) (92)
- A Phase II study of the polyamine analog N1,N11-diethylnorspermine (DENSpm) daily for five days every 21 days in patients with previously treated metastatic breast cancer. (2003) (92)
- Comparison of Paclitaxel-, 5-Fluoro-2′-deoxyuridine-, and Epidermal Growth Factor (EGF)-induced Apoptosis (1999) (92)
- BRCA1 expression in a large series of sporadic ovarian carcinomas: a Gynecologic Oncology Group study (2005) (85)
- Is the easier way ever the better way? (2011) (85)
- A comparison of cisplatin/paclitaxel and carboplatin/paclitaxel in stage IVB, recurrent or persistent cervical cancer. (2007) (82)
- Survival in Women With Grade 1 Serous Ovarian Carcinoma (2013) (81)
- Common variants in ABCB1, ABCC2 and ABCG2 genes and clinical outcomes among women with advanced stage ovarian cancer treated with platinum and taxane-based chemotherapy: a Gynecologic Oncology Group study. (2012) (81)
- Epithelial ovarian cancer. (2011) (78)
- A dual-center randomized controlled double blind trial assessing the effect of acupuncture in reducing musculoskeletal symptoms in breast cancer patients taking aromatase inhibitors (2013) (76)
- Centralization of care for patients with advanced‐stage ovarian cancer (2007) (76)
- Programmed cell death in an estrogen-independent human breast cancer cell line, MDA-MB-468. (1992) (75)
- Ovarian cancer, version 2.2013. (2013) (75)
- Bevacizumab in patients with advanced platinum-resistant ovarian cancer. (2006) (72)
- Relationship between ERCC1 polymorphisms, disease progression, and survival in the Gynecologic Oncology Group Phase III Trial of intraperitoneal versus intravenous cisplatin and paclitaxel for stage III epithelial ovarian cancer. (2008) (72)
- Comparison of breast cancer recurrence risk and cardiovascular disease incidence risk among postmenopausal women with breast cancer (2012) (71)
- Ovarian cancer clinical trial endpoints: Society of Gynecologic Oncology white paper. (2014) (68)
- Dabrafenib and Trametinib in Patients With Tumors With BRAFV600E Mutations: Results of the NCI-MATCH Trial Subprotocol H. (2020) (68)
- CA‐125 change after chemotherapy in prediction of treatment outcome among advanced mucinous and clear cell epithelial ovarian cancers (2009) (68)
- Breast cancer risk reduction. (2010) (66)
- Intraperitoneal therapy for stage III ovarian cancer: a therapy whose time has come! (2002) (66)
- Phase I trial and pharmacologic trial of sequences of paclitaxel and topotecan in previously treated ovarian epithelial malignancies: a Gynecologic Oncology Group study. (1997) (66)
- Factors affecting pharmacokinetic variability following doxorubicin and docetaxel-based therapy. (2004) (65)
- Altered formation of topotecan-stabilized topoisomerase I-DNA adducts in human leukemia cells. (1997) (64)
- Primary cytoreductive surgery and adjuvant hormonal monotherapy in women with advanced low-grade serous ovarian carcinoma: Reducing overtreatment without compromising survival? (2016) (64)
- A phase I trial of intraperitoneal sustained-release paclitaxel microspheres (Paclimer) in recurrent ovarian cancer: a Gynecologic Oncology Group study. (2006) (60)
- 0291: Secondary Cytoreductive Surgery for Localized Recurrent Epithelial Ovarian Cancer: Analysis of Prognostic Factors and Survival Outcome (2006) (58)
- A short-term biomarker modulation study of simvastatin in women at increased risk of a new breast cancer (2012) (58)
- The impact of disease distribution on survival in patients with stage III epithelial ovarian cancer cytoreduced to microscopic residual: a Gynecologic Oncology Group study. (2011) (57)
- NCCN Clinical Practice Guidelines in Oncology for Breast Cancer Risk Reduction (2010) (57)
- Large Prospective Study of Ovarian Cancer Screening in High-Risk Women: CA125 Cut-Point Defined by Menopausal Status (2011) (57)
- The prognostic value of pretreatment CA 125 in patients with advanced ovarian carcinoma (2009) (56)
- Phase I trial of bortezomib in combination with docetaxel in patients with advanced solid tumors. (2006) (56)
- Topotecan dosing guidelines in ovarian cancer: reduction and management of hematologic toxicity. (2004) (56)
- A phase III randomized controlled trial of secondary surgical cytoreduction (SSC) followed by platinum-based combination chemotherapy (PBC), with or without bevacizumab (B) in platinum-sensitive, recurrent ovarian cancer (PSOC): A NRG Oncology/Gynecologic Oncology Group (GOG) study. (2018) (55)
- Surgical care of elderly women with ovarian cancer: a population-based perspective. (2005) (55)
- An evaluation of progression free survival and overall survival of ovarian cancer patients with clear cell carcinoma versus serous carcinoma treated with platinum therapy: An NRG Oncology/Gynecologic Oncology Group experience. (2017) (52)
- Folate and folate receptor alpha antagonists mechanism of action in ovarian cancer. (2013) (52)
- Phase I trial of the matrix metalloproteinase inhibitor BAY12-9566 in patients with advanced solid tumors (2001) (52)
- Rucaparib for patients with platinum-sensitive, recurrent ovarian carcinoma (ARIEL3): post-progression outcomes and updated safety results from a randomised, placebo-controlled, phase 3 trial. (2020) (52)
- Optimizing the Use of Gene Expression Profiling in Early-Stage Breast Cancer. (2016) (51)
- The prognostic significance of pre- and post-treatment CA-125 in grade 1 serous ovarian carcinoma: a gynecologic Oncology Group study. (2012) (51)
- Recurrent micropapillary serous ovarian carcinoma (2002) (49)
- Secondary cytoreductive surgery for localized recurrent epithelial ovarian cancer: Analysis of prognostic factors and survival outcome (2006) (49)
- Clinical significance of Her-2/neu overexpression in uterine serous carcinoma. (2006) (49)
- Intraperitoneal cisplatin and paclitaxel versus intravenous carboplatin and paclitaxel chemotherapy for Stage III ovarian cancer: a cost-effectiveness analysis. (2007) (49)
- Intraperitoneal therapy for ovarian cancer: a treatment ready for prime time. (2006) (48)
- Ovarian cancer. Clinical practice guidelines in oncology. (2008) (48)
- BRCA1 and BRCA2 mutations in ethnic Lebanese Arab women with high hereditary risk breast cancer. (2015) (45)
- Clinical surveillance of gynecologic cancer patients. (1992) (44)
- Adjuvant therapy of completely resected dysgerminoma with carboplatin and etoposide: a trial of the Gynecologic Oncology Group. (2004) (44)
- OV21/PETROC: a randomized Gynecologic Cancer Intergroup phase II study of intraperitoneal versus intravenous chemotherapy following neoadjuvant chemotherapy and optimal debulking surgery in epithelial ovarian cancer (2018) (43)
- Cost effectiveness of intraperitoneal compared with intravenous chemotherapy for women with optimally resected stage III ovarian cancer: a Gynecologic Oncology Group study. (2008) (43)
- A phase III randomized controlled clinical trial of carboplatin and paclitaxel alone or in combination with bevacizumab followed by bevacizumab and secondary cytoreductive surgery in platinum-sensitive, recurrent ovarian, peritoneal primary and fallopian tube cancer (Gynecologic Oncology Group 0213) (2015) (43)
- A comparison of quality-of-life domains and clinical factors in ovarian cancer patients: a Gynecologic Oncology Group study. (2010) (42)
- The association between quality of life domains and overall survival in ovarian cancer patients during adjuvant chemotherapy: a Gynecologic Oncology Group Study. (2012) (42)
- Pre-treatment tumor expression of ERCC1 in women with advanced stage epithelial ovarian cancer is not predictive of clinical outcomes: a Gynecologic Oncology Group study. (2012) (41)
- Preliminary results of a phase II study: PD-1 blockade in mismatch repair–deficient, recurrent or persistent endometrial cancer (2016) (41)
- Exploratory phase II efficacy study of MORAb-003, a monoclonal antibody against folate receptor alpha, in platinum-sensitive ovarian cancer in first relapse (2008) (41)
- Assessment of factors that contribute to decreased quality of life in Gynecologic Oncology Group ovarian cancer trials (2009) (41)
- Racial disparities in the rate of cardiotoxicity of HER2‐targeted therapies among women with early breast cancer (2018) (40)
- Micropapillary serous ovarian carcinoma: surgical management and clinical outcome. (2002) (40)
- A final report of a phase I study of veliparib (ABT-888) in combination with low-dose fractionated whole abdominal radiation therapy (LDFWAR) in patients with advanced solid malignancies and peritoneal carcinomatosis with a dose escalation in ovarian and fallopian tube cancers. (2016) (40)
- Weight Change in Breast Cancer Survivors Compared to Cancer-Free Women: A Prospective Study in Women at Familial Risk of Breast Cancer (2015) (40)
- A phase I vaccine safety and chemotherapy dose-finding trial of an allogeneic GM-CSF-secreting breast cancer vaccine given in a specifically timed sequence with immunomodulatory doses of cyclophosphamide and doxorubicin. (2004) (39)
- A phase I trial of pegylated liposomal doxorubicin (PLD), carboplatin, bevacizumab and veliparib in recurrent, platinum-sensitive ovarian, primary peritoneal, and fallopian tube cancer: An NRG Oncology/Gynecologic Oncology Group study. (2015) (39)
- PROGNOSTIC VALUE OF PRETREATMENT CA-125 IN ADVANCED OVARIAN CARCINOMA: A GYNECOLOGIC ONCOLOGY GROUP STUDY (2009) (38)
- Anti-cancer therapy and clinical trial considerations for gynecologic oncology patients during the COVID-19 pandemic crisis☆ (2020) (38)
- A Randomized Phase II Trial of Epigenetic Priming with Guadecitabine and Carboplatin in Platinum-resistant, Recurrent Ovarian Cancer (2019) (36)
- Ovarian cancer. Clinical practice guidelines in oncology. (2006) (34)
- Management of Breast Cancer During the COVID-19 Pandemic: A Stage- and Subtype-Specific Approach. (2020) (33)
- FDA ovarian cancer clinical trial endpoints workshop: A Society of Gynecologic Oncology White Paper. (2017) (33)
- Hematologic safety and tolerability of topotecan in recurrent ovarian cancer and small cell lung cancer: an integrated analysis. (2005) (33)
- Phase I and pharmacologic study of the alkylating agent modulator novobiocin in combination with high-dose chemotherapy for the treatment of metastatic breast cancer. (1995) (32)
- Salvage cytoreductive surgery for recurrent endometrial cancer. (2006) (32)
- Hepsulfam sensitivity in human breast cancer cell lines: the role of glutathione and glutathione S-transferase in resistance. (1992) (31)
- Programmed death-1 blockade in mismatch repair deficient cancer independent of tumor histology. (2016) (30)
- Efficacy and safety of topotecan in the treatment of advanced ovarian carcinoma. (1997) (29)
- Nomogram for Predicting Individual Survival After Recurrence of Advanced-Stage, High-Grade Ovarian Carcinoma. (2019) (29)
- Ovarian Malignancy in Breast Cancer Patients With an Adnexal Mass (2005) (29)
- Life-threatening myelosuppression in patients with occult renal impairment receiving topotecan. (1997) (29)
- Changes in Breast Density and Circulating Estrogens in Postmenopausal Women Receiving Adjuvant Anastrozole (2011) (28)
- Phase I Study of MEDI3617, a Selective Angiopoietin-2 Inhibitor Alone and Combined with Carboplatin/Paclitaxel, Paclitaxel, or Bevacizumab for Advanced Solid Tumors (2018) (28)
- New Therapies for Ovarian Cancer. (2018) (27)
- Efficacy and safety of farletuzumab, a humanized monoclonal antibody to folate receptor alpha, in platinum-sensitive relapsed ovarian cancer subjects: Final data from a multicenter phase II study. (2010) (26)
- The Reliability of Nipple Aspirate and Ductal Lavage in Women at Increased Risk for Breast Cancer—a Potential Tool for Breast Cancer Risk Assessment and Biomarker Evaluation (2007) (26)
- Combination ATR and PARP Inhibitor (CAPRI): A phase 2 study of ceralasertib plus olaparib in patients with recurrent, platinum-resistant epithelial ovarian cancer. (2021) (26)
- The High Mobility Group A1 (HMGA1) gene is highly overexpressed in human uterine serous carcinomas and carcinosarcomas and drives Matrix Metalloproteinase-2 (MMP-2) in a subset of tumors. (2016) (25)
- Phase 1b safety study of farletuzumab, carboplatin and pegylated liposomal doxorubicin in patients with platinum-sensitive epithelial ovarian cancer☆,☆☆,★ (2015) (25)
- Role of farletuzumab in epithelial ovarian carcinoma. (2012) (25)
- Programmed cell death in human breast cancer cells. (1996) (25)
- A Gynecologic Oncology Group Study of serum CA-125 levels in patients with stage III optimally debulked ovarian cancer treated with intraperitoneal compared to intravenous chemotherapy: an analysis of patients enrolled in GOG 172. (2009) (24)
- Abdominal carcinomatosis in women with a history of breast cancer. (2005) (24)
- Analysis of Contemporary Trends in Access to High-Volume Ovarian Cancer Surgical Care (2009) (21)
- Patient-Centered Outcomes in ARIEL3, a Phase III, Randomized, Placebo-Controlled Trial of Rucaparib Maintenance Treatment in Patients With Recurrent Ovarian Carcinoma (2019) (20)
- Optic neuropathy from metastatic squamous cell carcinoma of the cervix: an unusual CNS presentation. (2006) (20)
- Autologous graft-versus-host disease induction in advanced breast cancer: role of peripheral blood progenitor cells (2000) (20)
- Immune-Related Adverse Events Requiring Hospitalization: Spectrum of Toxicity, Treatment, and Outcomes. (2019) (20)
- Pharmacoeconomic Impact of Critically Ill Surgical Patients (1988) (19)
- Phase I study of enzastaurin and bevacizumab in patients with advanced cancer: safety, efficacy and pharmacokinetics (2012) (18)
- Evaluation of osteopenia and osteoporosis in younger breast cancer survivors compared with cancer-free women: a prospective cohort study (2018) (17)
- A randomized phase II evaluation of bryostatin-1 (NSC #339555) in recurrent or persistent platinum-sensitive ovarian cancer: A Gynecologic Oncology Group Study (2003) (17)
- OV21/PETROC: A randomized Gynecologic Cancer Intergroup (GCIG) phase II study of intraperitoneal (IP) versus intravenous (IV) chemotherapy following neoadjuvant chemotherapy and optimal debulking surgery in epithelial ovarian cancer (EOC). (2016) (17)
- Evaluation of cancer-associated myositis and scleroderma autoantibodies in breast cancer patients without rheumatic disease. (2017) (17)
- Validation of FACT/GOG-AD subscale for ovarian cancer-related abdominal discomfort: a Gynecologic Oncology Group study. (2008) (16)
- A phase II "window" study of topotecan in untreated patients with high risk adult acute lymphoblastic leukemia. (1998) (16)
- African American women who receive primary anthracycline- and taxane-based chemotherapy for triple-negative breast cancer suffer worse outcomes compared with white women. (2009) (15)
- A phase II pharmacokinetic/pharmacogenetic (PK/PG) study using fixed-dose capecitabine in metastatic breast cancer (MBC). (2011) (15)
- Advancing Drug Development in Gynecologic Malignancies (2019) (15)
- Fixed-dose capecitabine is feasible: results from a pharmacokinetic and pharmacogenetic study in metastatic breast cancer (2013) (15)
- Apoptosis and Breast Cancer (1999) (15)
- A Phase II Study of the Polyamine Analog N 1 , N 11-Diethylnorspermine ( DENSpm ) Daily for Five Days Every 21 Days in Patients with Previously Treated Metastatic Breast Cancer (2003) (15)
- A phase I study with an expanded cohort to assess the feasibility of intravenous paclitaxel, intraperitoneal carboplatin and intraperitoneal paclitaxel in patients with untreated ovarian, fallopian tube or primary peritoneal carcinoma: a Gynecologic Oncology Group study. (2012) (14)
- Frontline PARP inhibitor maintenance therapy in ovarian cancer: A Society of Gynecologic Oncology practice statement. (2020) (14)
- NCCN Guidelines® Insights: Ovarian Cancer, Version 3.2022. (2022) (14)
- Role of Intraperitoneal Therapy in the Initial Management of Ovarian Cancer. (2019) (14)
- A randomized phase II evaluation of bryostatin-1 (NSC #339555) in persistent or recurrent squamous cell carcinoma of the cervix: A Gynecologic Oncology Group Study (2003) (14)
- Baseline quality of life (QOL) as a predictor of tolerance to intraperitoneal (IP) chemotherapy for advanced epithelial ovarian cancer (EOC): A Gynecologic Oncology Group (GOG) study. (2006) (14)
- A phase I study of paclitaxel, topotecan, cisplatin and Filgrastim in patients with newly diagnosed advanced ovarian epithelial malignancies: a Gynecologic Oncology Group study. (2007) (14)
- A phase I study with an expanded cohort to assess feasibility of intravenous docetaxel, intraperitoneal carboplatin and intraperitoneal paclitaxel in patients with previously untreated ovarian, fallopian tube or primary peritoneal carcinoma: a Gynecologic Oncology Group study. (2012) (13)
- Breast cancer risk reduction. (2010) (13)
- A phase 2 study of live-attenuated listeria monocytogenes cancer immunotherapy (ADXS11-001) in the treatment of persistent or recurrent cancer of the cervix (GOG-0265). (2012) (13)
- Pathologic complete response to preoperative sequential doxorubicin/cyclophosphamide and single-agent taxane with or without trastuzumab in stage II/III HER2-positive breast cancer. (2010) (13)
- Combination of PARP and ATR inhibitors (olaparib and ceralasertib) shows clinical activity in acquired PARP inhibitor-resistant recurrent ovarian cancer. (2021) (13)
- A phase 2 biomarker trial of combination cediranib and olaparib in relapsed platinum (plat) sensitive and plat resistant ovarian cancer (ovca). (2018) (13)
- Novobiocin in combination with high-dose chemotherapy for the treatment of advanced breast cancer: a phase 2 study. (2000) (13)
- Breast Cancer Risk Reduction Clinical Practice Guidelines in Oncology. (2007) (12)
- Differences in presentation and survival of Asians compared to Caucasians with ovarian cancer: An NRG Oncology/GOG Ancillary study of 7914 patients. (2019) (12)
- A phase 1 study of MORAb-009, a monoclonal antibody against mesothelin in pancreatic cancer, mesothelioma and ovarian adenocarcinoma (2007) (12)
- A phase II randomized study of avelumab plus entinostat versus avelumab plus placebo in patients (pts) with advanced epithelial ovarian cancer (EOC). (2019) (12)
- Long-term survival advantage of intraperitoneal chemotherapy treatment in advanced ovarian cancer: An analysis of a Gynecologic Oncology Group ancillary data study (2013) (12)
- Update on treatment options for newly diagnosed ovarian cancer. (2010) (12)
- Dose intensity for breast cancer. (2001) (12)
- Feasibility trial of partial breast irradiation with concurrent dose-dense doxorubicin and cyclophosphamide in early-stage breast cancer. (2009) (12)
- Dabrafenib and trametinib in patients with tumors with BRAF V600E/K mutations: Results from the molecular analysis for therapy choice (MATCH) Arm H. (2019) (11)
- The Effects of a Remote-based Weight Loss Program on Adipocytokines, Metabolic Markers, and Telomere Length in Breast Cancer Survivors: the POWER-Remote Trial (2020) (10)
- Selecting endocrine therapy for breast cancer: what role does HER-2/neu status play? (2006) (10)
- Phase I trial of bortezomib (PS-341) in combination with docetaxel in patients with advanced solid tumors. (2004) (10)
- A multi-institutional double-blind phase II study evaluating response and surrogate biomarkers to carboplatin and nab-paclitaxel (CP) with or without vorinostat as preoperative systemic therapy (PST) in HER2-negative primary operable breast cancer (TBCRC008). (2010) (10)
- Quality of life (QOL) results of a randomized study of intravenous (IV) paclitaxel and cisplatin vs IV paclitaxel, intraperitoneal (IP) cisplatin and IP paclitaxel in optimal stage III epithelial ovarian cancer (OC): A Gynecologic Oncology Group trial (2004) (10)
- A phase II Trial of EMD72000 (matuzumab), a humanized anti-EGFR monoclonal antibody in subjects with heavily treated and platinum-resistant advanced Mullerian malignancies (2005) (9)
- The effect of age on efficacy, safety and patient-centered outcomes with rucaparib: A post hoc exploratory analysis of ARIEL3, a phase 3, randomized, maintenance study in patients with recurrent ovarian carcinoma (2020) (9)
- Does time interval between surgery and intraperitoneal chemotherapy administration in advanced ovarian cancer carry a prognostic impact? An NRG Oncology/Gynecologic Oncology Group study ancillary study. (2016) (8)
- Identification and characterization of a spontaneous ovarian carcinoma in Lewis rats (2010) (8)
- Assessment of the Prognostic Value of Two Common Variants of BRCA1 and BRCA2 Genes in Ovarian Cancer Patients Treated with Cisplatin and Paclitaxel: A Gynecologic Oncology Group Study (2013) (8)
- A phase I study of intravenous or intraperitoneal platinum based chemotherapy in combination with veliparib and bevacizumab in newly diagnosed ovarian, primary peritoneal and fallopian tube cancer. (2019) (8)
- Phase I safety study of farletuzumab, carboplatin, and pegylated liposomal doxorubicin (PLD) in subjects with platinum-sensitive epithelial ovarian cancer (EOC). (2011) (7)
- 8000 Efficacy and safety of farletuzumab, a humanized monoclonal antibody to folate receptor alpha, in platinum-sensitive relapsed ovarian cancer subjects: preliminary data from a phase-2 study (2009) (7)
- Bevacizumab after bevacizumab in platinum-sensitive recurrent ovarian cancer: A subgroup analysis of GOG0213. (2016) (7)
- Sixteen week dose intense chemotherapy for inoperable, locally advanced breast cancer (2004) (6)
- A phase I study of veliparib incorporated into front-line platinum based cheotherpy and bevacizumab in epithelial ovarian cancer (NCT00989651): A GOG/nrg trial. (2019) (6)
- Phase I study of enzastaurin (ENZ) and bevacizumab (BV) in patients with advanced cancer: Safety, pharmacokinetics (PK), and response assessment. (2008) (6)
- New issues in systemic therapy for ovarian cancer. (2013) (6)
- The reliability of ductal lavage in women at high risk for breast cancer (2005) (5)
- Genome-wide association study evaluating single-nucleotide polymorphisms and outcomes in patients with advanced stage serous ovarian or primary peritoneal cancer: An NRG Oncology/Gynecologic Oncology Group study. (2014) (5)
- A prospective multi-center ovarian cancer screening study in women at increased risk (2007) (5)
- A randomized, double-blind, placebo-controlled phase II study of the efficacy and safety of farletuzumab (MORAb-003) in combination with weekly paclitaxel in subjects with platinum-resistant or refractory relapsed ovarian cancer. (2010) (5)
- Quality of life (QOL) results of a randomized study of intravenous (IV) paclitaxel and cisplatin vs IV paclitaxel, intraperitoneal (IP) cisplatin and IP paclitaxel in optimal stage III epithelial ovarian cancer (OC): A Gynecologic Oncology Group trial. (2004) (5)
- NCCN CLINICAL PRACTICE GUIDELINES IN ONCOLOGY Ovarian Cancer, Version 2.2020 (2021) (4)
- Final report on serial phase II trials of all-intraperitoneal chemotherapy with or without bevacizumab for women with newly diagnosed, optimally cytoreduced carcinoma of Müllerian origin. (2019) (4)
- The association between quality of life and overall survival in ovarian cancer patients during adjuvant chemotherapy: A Gynecologic Oncology Group study. (2010) (4)
- Randomized phase III trial of carboplatin/paclitaxel alone (CP) or in combination with bevacizumab followed by bevacizumab (CPB) and secondary cytoreduction surgery in platinum-sensitive recurrent ovarian cancer: GOG0213, an NRG Oncology/GOG Study—Analysis of patient reported outcomes (PRO) on chemo (2015) (4)
- Olaparib Use in Patients With Metastatic Breast Cancer Harboring Somatic BRCA1/2 Mutations or Mutations in Non-BRCA1/2, DNA Damage Repair Genes. (2021) (4)
- Rucaparib maintenance treatment for recurrent ovarian carcinoma: the effects of progression-free interval and prior therapies on efficacy and safety in the randomized phase III trial ARIEL3 (2021) (4)
- Early Diagnosis and Treatment of Cancer Series: Ovarian Cancer (2009) (4)
- Intraperitoneal chemotherapy for advanced epithelial ovarian cancer: many questions, much promise.... (2011) (4)
- A Gynecologic Oncology Group study of associations between polymorphisms in ABC transporter genes (ABCB1, ABCC2, and ABCG2) and outcome in advanced stage epithelial ovarian cancer treated with platinum and taxane chemotherapy. (2009) (4)
- A phase I study of MORab-009, a monoclonal antibody against mesothelin, in mesothelioma, pancreatic and ovarian cancer (2008) (3)
- Feasibility of Intravenous Gemcitabine and an Intraperitoneal Platinum Agent in the Treatment of Ovarian Cancer (2011) (3)
- The estrogen receptor-alpha S118P variant does not affect breast cancer incidence or response to endocrine therapies (2019) (3)
- Maintenance treatment with rucaparib for recurrent ovarian carcinoma in ARIEL3, a randomized phase 3 trial: The effects of best response to last platinum‐based regimen and disease at baseline on efficacy and safety (2021) (3)
- Validation of a FACT/GOG-Abdominal Discomfort (AD) subscale: A Gynecologic Oncology Group (GOG) study (2005) (3)
- Immune-related adverse events requiring inpatient management: Spectrum of toxicity, treatment, and outcomes. (2018) (3)
- Ovarian cancer clinical practice guidelines. (2004) (3)
- Novel Therapies in Ovarian Cancer Management: An Update on the Role of Topotecan (2002) (3)
- Breast cancer. (2014) (3)
- Reply to W.R. Robinson (2012) (3)
- Association of treatment-emergent symptoms identified by patient-reported outcomes with adjuvant endocrine therapy discontinuation (2022) (3)
- A phase 1 study of MEDI3617, a selective angiopoietin-2 inhibitor, alone and in combination with carboplatin/paclitaxel, paclitaxel, or bevacizumab in patients with advanced solid tumors. (2014) (3)
- Post hoc analyses of GOG 9923: Does BRCA status affect toxicities?: An NRG oncology study. (2021) (3)
- Breast cancer screening adherence at multiple timepoints over eight years among women in a familial cohort. (2019) (3)
- Emerging therapeutic options for platinum-sensitive ovarian cancer patients. (2011) (2)
- Phase I/II Trial of Partial Breast Irradiation With Concurrent Dose-Dense Doxorubicin and Cyclophosphamide (ddAC) Chemotherapy in Early Stage Breast Cancer: Report of Skin Toxicity and Cosmetic Outcome (2007) (2)
- The clinical-pathologic factors relevant to intraperitoneal chemotherapy in ovarian cancer: An analysis of two Gynecologic Oncology Group trials (2008) (2)
- A phase I study of diethylnorspermine (DENSPM) in previously treated patients with metastatic breast cancer (MBC) (2001) (2)
- Abstract P3-12-02: Predictors of adherence to adjuvant endocrine therapy (ET) for early breast cancer (BC) in a prospective clinic-based cohort (2018) (2)
- A Phase I Toxicity and Feasibility Trial of Sequential Dose-Dense Induction Chemotherapy with Doxorubicin, Paclitaxel, and 5-Fluorouracil Followed by High Dose Consolidation for High-Risk Primary Breast Cancer (2002) (2)
- Postprogression outcomes in patients with ovarian carcinoma associated with a mutation in a non-BRCA homologous recombination repair gene receiving rucaparib maintenance treatment: Results from the phase III study ARIEL3 (2020) (2)
- Administration guidelines for intraperitoneal chemotherapy for ovarian cancer (2010) (2)
- Abstract A72: Combination ATR and PARP inhibitor (CAPRI) for recurrent, platinum-resistant ovarian cancer (2020) (2)
- Intraperitoneal treatment in ovarian cancer: the gynecologic oncology group perspective in 2012. (2012) (2)
- Partial breast irradiation (PBI) concurrent with adjuvant dose-dense doxorubicin and dyclophosphamide (ddAC) chemotherapy in early-stage breast cancer: Preliminary safety results from a feasibility trial. (2006) (2)
- Hyperthermic Intraperitoneal Chemotherapy for the Treatment of Epithelial Ovarian Cancer. (2022) (2)
- Intraperitoneal Chemotherapy for Stage III Ovarian Cancer Using the Gynecologic Oncology Group Protocol 172 Intraperitoneal Regimen: Effect of Supportive Care Using Aprepitant and Pegfilgrastim on Treatment Completion Rate (2008) (2)
- 3 Postprogression efficacy outcomes from the phase 3 ARIEL3 study of rucaparib in patients with platinum-sensitive recurrent ovarian carcinoma associated with either BRCA1 or BRCA2 mutations (2020) (1)
- HPTN 069/ACTG A5305: phase II study of maraviroc-containing regimens for HIV PrEP in US women; Postive impact of a randomized controlled trial of the Uthando Lwethu ("Our Love") intervention on rates of couples HIV testing in rural South Africa (2016) (1)
- What proportion of patients with stage 3 ovarian cancer are potentially cured following intraperitoneal chemotherapy? Analysis of the long term (≥10 years) survivors in NRG/GOG randomized clinical trials of intraperitoneal and intravenous chemotherapy in stage III ovarian cancer (2022) (1)
- Durable Responses to PD-1 Blockade in Mismatch-Repair Deficient Cancers, Independent of Tissue Origin (2017) (1)
- Use of PARP Inhibitors for Ovarian Cancer (2021) (1)
- NCCN Breast Cancer Risk Reduction Clinical Practice Guidelines in Oncology (2010) (1)
- Novel phase II study design of MORAb-003, a monoclonal antibody against folate receptor alpha in platinum-sensitive ovarian cancer in first relapse (2007) (1)
- Partial breast irradiation (PBI) concurrent with adjuvant dose-dense doxorubicin and dyclophosphamide (ddAC) chemotherapy in early-stage breast cancer: Preliminary safety results from a feasibility trial (2006) (1)
- AML and MDS associated with PARP inhibitor treatment of ovarian cancer. (2022) (1)
- Tolerability and pharmacokinetics of intraperitoneal carboplatin and paclitaxel with intravenous bevacizumab. (2010) (1)
- Long-Term Survival Advantage and Prognostic Factors Associated With Intraperitoneal Chemotherapy Treatment in Advanced Ovarian Cancer: A Gynecologic Oncology Group Study (2015) (1)
- In assessing surrogate clinical trial end points: drug safety is a requisite. (2015) (1)
- Mammographic, MRI, and ultrasound characteristics of BRCA1, BRCA2, and other genetically high-risk women enrolled in a prospective multi-institution breast cancer screening trial. (2004) (1)
- Blood-based biomarkers in patients with platinum-sensitive and resistant ovarian cancer treated with olaparib and cediranib: results from the UM9825 trial (2021) (1)
- Dose intensity for breast cancer: where do we go from here? (2001) (1)
- Nomogram predicting individual survival following recurrence in advanced stage high-grade ovarian cancer from NRG Oncology/Gynecologic Oncology Group randomized trials of platinum and paclitaxel (2017) (1)
- Abdominal Carcinomatosis in Women with a History of Breast Cancer (2006) (1)
- A randomized, double-blind, placebo-controlled, phase II study to assess the efficacy and safety of farletuzumab (MORAb-003) in combination with carboplatin plus either paclitaxel or pegylated liposomal doxorubicin (PLD) in subjects with low CA125 platinum-sensitive ovarian cancer. (2016) (1)
- Commentary (Brown/Armstrong): Pregnancy and Breast Cancer (2005) (0)
- Outcomes of African American (AA) versus caucasian (CA) women with triple-negative (TN) breast cancer following preoperative anthracycline and taxane-based chemotherapy (2008) (0)
- The authors reply [8] (2006) (0)
- Epithelial Ovarian CancerPractice Guidelines in Oncology (2011) (0)
- Analysis of prognostic factors and survival outcome following secondary cytoreductive surgery for localized, recurrent epithelial ovarian cancer (2007) (0)
- Intraperitoneal chemotherapy in ovarian cancer remains experimental. Commentary (2006) (0)
- Characterizing benign breast disease in women at high risk for breast cancer. (2010) (0)
- Association of treatment-emergent symptoms identified by patient-reported outcomes with adjuvant endocrine therapy discontinuation (2022) (0)
- The "luxury" of second malignancies. (2011) (0)
- A Phase II Study of the Polyamine Analog N,N- Diethylnorspermine (DENSpm) Daily for Five Days Every 21 Days in Patients with Previously Treated Metastatic Breast Cancer (2003) (0)
- Although ovarian cancer may spread to distant sites via the bloodstream and / or nodal system , most of the Overview of Ovarian Cancer (2013) (0)
- The Many Challenges of Neoadjuvant Chemotherapy for Ovarian Cancer (2008) (0)
- Planning treatment for women with recurrent epithelial ovarian cancer. (2013) (0)
- Vulnerable Older Adults With Ovarian Cancer-Time to Stop Undertreating. (2021) (0)
- Uterine MEIS1::NCOA2 Fusion Sarcoma With Lung Metastasis: A Case Report and Review of the Literature. (2023) (0)
- Changes in patient-reported outcomes in women with breast cancer in a multicenter double-blind randomized controlled trial assessing the effect of acupuncture in reducing aromatase inhibitor-induced musculoskeletal symptoms (AIMSS). (2012) (0)
- 767 poster PARTIAL BREAST IRRADIATION WITH CONCURRENT DOSE DENSE DOXORUBICIN & CYCLOPHOSPHAMIDE: LATE TOXICITY & RECURRENCE (2011) (0)
- Abstract P4-10-06: Factors impacting the accuracy of self-reported breast procedures among women with and without breast cancer (2019) (0)
- Research Summaries: The 11th Biennial Rivkin Center Ovarian Cancer Research Symposium (2017) (0)
- Introduction: the 12th Biennial Rivkin Center Ovarian Cancer Research Symposium (2019) (0)
- Abstract 2423: Longitudinal examination of breast cancer screening adherence among women in a prospective familial cohort (2019) (0)
- Abstract CT056: A multicenter, open-label phase 1/2 trial evaluating the safety, tolerability, and efficacy of MORAb-202, a folate-receptor-alpha-targeting antibody-drug conjugate in patients with selected tumor types (2023) (0)
- Abstract A074: Correlation of homologous recombination deficiency (HRD) status by BROCA-HR sequencing with response to combination cediranib and olaparib in relapsed ovarian cancer (2019) (0)
- Surgical management of peritoneal carcinomatosis in ovarian cancer (2014) (0)
- Tolerability and adverse events experienced by women with ovarian cancer treated with intravenous or intraperitoneal chemotherapy plus veliparib and bevacizumab based on BRCA status (2020) (0)
- 750 poster COSMETIC OUTCOME AFTER PARTIAL BREAST IRRADIATION WITH CONCURRENT CHEMOTHERAPY IN EARLY-STAGE BREAST CANCER (2011) (0)
- Phase I Trial of Intravenous Mistletoe Extract in Advanced Cancer (2023) (0)
- Outcomes based on treatment regimen in newly diagnosed ovarian, primary peritoneal and fallopian tube cancer receiving intravenous or intraperitoneal platinum-based chemotherapy in combination with veliparib and bevacizumab (2020) (0)
- Abstract 3271: Evaluation of bone health in breast cancer survivors compared to cancer-free women: A prospective study within a young familial risk cohort (2017) (0)
- Evaluation of osteopenia and osteoporosis in younger breast cancer survivors compared with cancer-free women: a prospective cohort study (2018) (0)
- Abstract B25: Information on perceived breast cancer risk may help tailor risk assessment among high risk women (2008) (0)
- 2022-RA-1241-ESGO A multicentre, open-label phase 1/2 trial evaluating the safety, tolerability, and efficacy of morab-202, a folate receptor alpha-targeting antibody-drug conjugate in patients with selected tumour types (2022) (0)
- Pregnancy and breast cancer: Epidemiology, treatment, and safety issues - Commentary (2005) (0)
- Thanks to authors and peer reviewers (2008) (0)
- Abstract P6-10-11: Longitudinal comparison of weight change in breast cancer survivors to cancer-free women: a prospective study in women with a familial risk of breast cancer (2015) (0)
- Hypothermia for Neonates with Hypoxic-Ischemic Encephalopathy (2006) (0)
- Breast Cancer Cell Line , MDA-MB-468 Programmed Cell Death in an Estrogen-independent Human Updated (2006) (0)
- Randomized phase II trial of farletuzumab plus chemotherapy versus placebo plus chemotherapy in low CA-125 platinum-sensitive ovarian cancer. (2023) (0)
- Current endocrine therapy options for postmenopausal women with early-stage hormone receptor-positive breast cancer (2005) (0)
- Programmed Cell Death in an Estrogen-independent Human Breast Cancer Cell Line , MDA-MB-4681 (2006) (0)
- Effect of lymphopenia on survival in women with cervical cancer treated with primary chemoradiation. (2014) (0)
- Longitudinal comparison of body mass index (BMI) in breast cancer survivors to cancer-free women: A prospective study in high-risk women. (2013) (0)
- Borderline Tumors and Other Rare Epithelial Tumors of the Ovary (2012) (0)
- Nadir CA125 and second look surgery in patients with advanced stage epithelial ovarian cancer treated with intravenous compared to intraperitoneal chemotherapy: A study of Gynecologic Oncology Group Protocols 114 and 172 (2012) (0)
- Roundtable discussion: Current standard of care for adjuvant hormonal treatment of breast cancer (2005) (0)
- Does Intraperitoneal Therapy for Ovarian Cancer Have a Future (2014) (0)
- Abstract 3568: Progression from benign breast disease to cancer in women with a family history of breast cancer (2012) (0)
- Abstract P6-08-12: Understanding the etiology of osteopenia and osteoporosis in young breast cancer survivors compared to cancer-free women (2018) (0)
- Outcomes of newly diagnosed stage II ovarian, primary peritoneal and fallopian tube cancer receiving intravenous or intraperitoneal platinum based chemotherapy in combination with veliparib and bevacizumab (2020) (0)
- IP therapy in front-line care for advanced ovarian cancer (2007) (0)
- Intraperitoneal chemotherapy for ovarian cancer (2015) (0)
- Characterization and predictors of long term (≥ 10 years) survivors in NRG/GOG randomized clinical trials of intraperitoneal and intravenous chemotherapy in stage III ovarian cancer patients. (2018) (0)
- Does time interval between surgery and intraperitoneal chemotherapy administration in advanced ovarian cancer carry a prognostic impact (2015) (0)
- Abstract P1-03-06: BRCA1 and BRCA2 mutations in ethnic Lebanese Arab high risk women for hereditary breast cancer (2015) (0)
- Abstract 2544: Association between flame-broiled fish consumption and breast cancer: A case-control study in women with high familial risk (2016) (0)
- INTRAPERITONEAL CATHETER OUTCOMES ON GOG 172: A GYNECOLOGIC ONCOLOGY GROUP STUDY IN WOMEN WITH OPTIMALLY DEBULKED STAGE III OVARIAN CANCER (2004) (0)
- Management of acute and chronic complications of gynecologic cancer treatment (2013) (0)
- Abstract P3-03-17: The Impact of Cardiovascular Disease Risk on Cancer Progression among Female Breast Cancer Survivors: A Longitudinal Study within The Boss Cohort (2023) (0)
- Comprar Early Diagnosis of Cancer Series: Ovarian Cancer | Robert Bristow | 9781416046851 | Saunders (2008) (0)
- Focused Plenary Focused Plenary Session II-Translational Research Abstracts 16-21 16 BRCA1/BRCA2 polymorphisms and prognosis in women with optimally resected stage III epithelial ovarian cancer treated on GOG protocol 172: A Gynecologic Oncology Group study (2009) (0)
- A phase I dose escalation study of AGS-8M4 (ASP6183), an anti-AGS-8 fully human antibody, in advanced ovarian cancer. (2010) (0)
- Combination ATR (ceralasertib) and PARP (olaparib) Inhibitor (CAPRI) trial in acquired PARP-inhibitor-resistant homologous recombination deficient ovarian cancer. (2023) (0)
- A randomized, double-blind, placebo-controlled, phase II study to assess the efficacy/safety of farletuzumab in combination with carboplatin plus paclitaxel or carboplatin plus pegylated liposomal doxorubicin (PLD) in women with low CA-125 platinum-sensitive ovarian cancer (2021) (0)
- Delayed recurrences and survival after relapse in patients initially treated with intraperitoneal chemotherapy for advanced ovarian cancer: A Gynecologic Oncology Group study. (2015) (0)
- In reply [2] (2006) (0)
This paper list is powered by the following services:
What Schools Are Affiliated With Deborah Kay Armstrong?
Deborah Kay Armstrong is affiliated with the following schools:
